Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab.
about
High-grade glioma management and response assessment-recent advances and current challengesCurrent standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patientsAntiangiogenic therapy of brain tumors: the role of bevacizumab.Imaging biomarkers for antiangiogenic therapy in malignant gliomas.Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.An Update on the Approach to the Imaging of Brain Tumors.Quantitative MRI for analysis of peritumoral edema in malignant gliomasQuantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapyVascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.Tumor-associated edema in brain cancer patients: pathogenesis and management.Multimodal imaging based on MRI and PET reveals [(18)F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma.Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma.MR Fingerprinting of Adult Brain Tumors: Initial Experience.18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.Differentiation between vasogenic edema and infiltrative tumor in patients with high-grade gliomas using texture patch-based analysis.Improved visibility of brain tumors in synthetic MP-RAGE anatomies with pure T1 weighting.Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI.Imaging in neuro-oncology.
P2860
Q26740664-0AC6F62E-514F-480A-BE2D-A3781356AC56Q26853308-630A0BD6-9057-48ED-B23F-6062C1D368E9Q30737224-393C7C76-2A6A-407B-8AD4-00B206E82E92Q30764736-18DF9F12-49DF-4CC6-A97D-69CB322009ADQ30907831-46F4FA46-3239-4325-8DD0-2FA410EB3F87Q35895174-06307847-3865-45DC-9B0C-2DB8582CD755Q36374577-8AFDFB0A-6560-40AC-94E6-DA543BCBC390Q36380888-87444382-28D8-4CBB-AB5A-8A88F1B005DFQ36627187-A44E700F-692D-4366-90CF-5FED83BAB0E1Q36713499-8358804B-7E52-4F3B-A672-2C3DB4FE9168Q36943903-0D768768-5212-4AAF-9F69-1617E1EBD936Q37187727-02FD1D51-68A1-4132-A63B-FF792697D182Q38154959-0E139897-EF0B-431F-BA4B-B80A3788AF6BQ38822001-AD6D60DC-C53B-4BA3-9169-F819C04CEED3Q38897023-D83BE752-E596-45A9-A816-2C1D5336815AQ38904605-3F625196-E2AC-4623-B480-215AB1C451A9Q40402415-1FFADE45-7DDA-405C-AA0F-513A0D317860Q41877778-BF4F2578-249D-403C-966B-BDABA712ECC9Q47191350-7427AD23-6271-4094-9622-6FCA5975182BQ48184512-D3A08D02-28A6-4350-B796-9794314F692CQ48191891-46ABD649-F208-484E-8B12-B90F6119840BQ48495257-75D18B96-EB4A-49F3-A2B9-5D6FCE2DACFBQ54973707-DEE16F44-79A4-42AD-BEB3-85728ED07D8F
P2860
Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Quantification of edema reduct ...... toma treated with bevacizumab.
@en
Quantification of edema reduction using differential quantitative T2
@nl
type
label
Quantification of edema reduct ...... toma treated with bevacizumab.
@en
Quantification of edema reduction using differential quantitative T2
@nl
prefLabel
Quantification of edema reduct ...... toma treated with bevacizumab.
@en
Quantification of edema reduction using differential quantitative T2
@nl
P2093
P2860
P1476
Quantification of edema reduct ...... toma treated with bevacizumab.
@en
P2093
Albert Lai
Benjamin M Ellingson
Kourosh Motevalibashinaeini
Paul S Mischel
Phioanh L Nghiemphu
Shadi Lalezari
Taryar Zaw
Timothy F Cloughesy
Whitney B Pope
P2860
P2888
P304
P356
10.1007/S11060-011-0638-X
P577
2011-06-25T00:00:00Z